Cross-Sector entity

Steris plc

Company STE
5.7

Of the tracked stories, 2 of 3 also mention Activest Wealth Management, the most common co-covered peer. That works out to roughly 0.1 stories per week across a 158-day span. The busiest single day carried 2. The clearest coverage concentration is markets: 1 of 3 stories, with the rest divided among 2 other categories.

3 verified stories tracked

Last mentioned: Aug 17, 2026

RSS updates
Share

Entity pulse

Recent coverage · Steris plc

↑
3 stories
5.7 avg impact
0% positive
33% negative

Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 33 percentage points.

  • 67% neutral
  • 33% negative

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Steris plc

Of the tracked stories, 2 of 3 also mention Activest Wealth Management, the most common co-covered peer. That works out to roughly 0.1 stories per week across a 158-day span. The busiest single day carried 2. The clearest coverage concentration is markets: 1 of 3 stories, with the rest divided among 2 other categories. Steris plc appears in 3 tracked Cross-Sector stories published from March 13, 2026 through August 17, 2026. Each carries 2.3 original sources on average.

Stories tracked
3
Per week
0.1
Sources per story
2.3

Computed from the 3 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Steris plc. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. STE trading level

    STERIS shares opened at $232.88, within a 52-week range of $195.14 to $269.44.

  2. Director Breeden insider sale

    STERIS director Richard C. Breeden sold 1,481 shares at an average price of $209.51, totaling $310,284.31 — a 3.66% reduction leaving 38,964 shares directly owned.

  3. Q2 2026 new positions

    Stoneridge Investment Partners initiated a new 4,497-share stake valued at $1,027,000. Elevation Wealth Partners raised its stake 1,130% to 123 shares ($26,000).

  4. Q1 2026 institutional accumulation

    Goldman Sachs lifted its position 32.3% to 242,732 shares ($55.0M). Jane Street increased 38.9% to 20,716 shares ($4.7M). Woodline Partners grew 40.0% to 8,300 shares ($1.88M). Jones Financial raised 46.1%. Empowered Funds added 16.1%. Geneos Wealth grew 416.0%. Western Wealth opened a new $25,000 stake.

  5. Q4 2025 13F filings

    Activest Wealth Management raised its STERIS stake 423.8% to 110 shares ($28,000), and Measured Wealth Private Client Group opened a new position valued at about $28,000.

Stories mentioning Steris plc 3

Healthcare medical devices Neutral 5

STERIS Institutional Ownership Hits 94.69% on 32.3% Goldman Boost

A wave of institutional accumulation in STERIS plc — including a 32.3% Goldman Sachs position increase and a new $1.03 million Stoneridge stake in Q2 2026 — signals confidence in the medical equipment provider's infection-prevention franchise. With institutions now holding 94.69% of shares and the company maintaining a 0.23 debt-to-equity ratio, STERIS appears positioned to absorb hospital capital-expenditure cycles. A modest June insider sale by director Richard C. Breeden at $209.51 is a minor contrarian signal in an otherwise bullish institutional pattern.

2 sources
Finance markets Neutral 5

Goldman Sachs Ups STERIS 32.3% as Institutions Own 94.69%

STERIS plc's latest 13F disclosures show a broad institutional accumulation wave: Goldman Sachs raised its stake 32.3% to 242,732 shares ($55M) in Q1, and Stoneridge Investment Partners opened a new $1.03M position in Q2. With 94.69% of the float owned by institutions and a director selling $310K of stock in June, the signals are mixed. Conservative leverage (debt-to-equity 0.23) and a 1.35 quick ratio support the long case.

2 sources

Source: tickerreport.com · dailypolitical.com

Biotech pharma Negative 7

EPA Relaxes Ethylene Oxide Emission Standards for Medical Sterilizers

The Environmental Protection Agency (EPA) has moved to ease pollution restrictions on ethylene oxide (EtO), a critical chemical used to sterilize half of all U.S. medical devices. This regulatory shift aims to prevent potential healthcare supply chain disruptions but faces immediate backlash from environmental and public health advocates.

3 sources